← Back to Search

Insulin

Active drugs for Type 1 Diabetes

Phase 3
Waitlist Available
Led By Nitesh D Kuhadiya, MD, MPH
Research Sponsored by University at Buffalo
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Study Summary

This trial is studying if adding a GLP-1 agonist or SGLT2 inhibitor to diabetes treatment can improve blood sugar control, insulin usage, weight, and blood pressure.

Eligible Conditions
  • Type 1 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Absolute Change After 12 Weeks From Baseline in Mean HbA1c With Addition of Dapagliflozin Compared to Placebo.
Secondary outcome measures
Change in 24-hour Urine Glucose Excretion.
Change in Blood Ketone Bodies
Change in Body Weight
+3 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Active drugsActive Control3 Interventions
12 weeks of treatment with Insulin, Liraglutide and "Active Dapagliflozin Drug"
Group II: PlaceboPlacebo Group3 Interventions
12 weeks of treatment with Insulin, Liraglutide and "Dapagliflozin Placebo"

Find a Location

Who is running the clinical trial?

University at BuffaloLead Sponsor
131 Previous Clinical Trials
98,933 Total Patients Enrolled
Nitesh D Kuhadiya, MD, MPHPrincipal InvestigatorUniversity at Buffalo

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes
Paresh Dandona 2015. "Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02518945.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top